Literature DB >> 24625550

Disseminated tuberculosis associated with ruxolitinib.

R K Hopman1, S J Lawrence2, S T Oh1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24625550     DOI： 10.1038/leu.2014.104

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Authors:  Rowan Wathes; Simon Moule; Dragana Milojkovic
Journal:  N Engl J Med       Date:  2013-07-11       Impact factor: 91.245

2.  Bilateral toxoplasmosis retinitis associated with ruxolitinib.

Authors:  Roger A Goldberg; Elias Reichel; Lauren J Oshry
Journal:  N Engl J Med       Date:  2013-08-15       Impact factor: 91.245

3.  Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis.

Authors:  G Caocci; F Murgia; L Podda; A Solinas; S Atzeni; G La Nasa
Journal:  Leukemia       Date:  2013-08-09       Impact factor: 11.528

4.  Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib.

Authors:  M Massa; V Rosti; R Campanelli; G Fois; G Barosi
Journal:  Leukemia       Date:  2013-10-22       Impact factor: 11.528

5.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

6.  Ruxolitinib targets DCs: for better or worse?

Authors:  Ayalew Tefferi
Journal:  Blood       Date:  2013-08-15       Impact factor: 22.113

7.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

8.  The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Authors:  Annkristin Heine; Stefanie Andrea Erika Held; Solveig Nora Daecke; Stephanie Wallner; Sowmya Parampalli Yajnanarayana; Christian Kurts; Dominik Wolf; Peter Brossart
Journal:  Blood       Date:  2013-06-14       Impact factor: 22.113

9.  An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Authors:  Nicholas G Wysham; Donald R Sullivan; Gopal Allada
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report.

Authors:  Claudia Colomba; Raffaella Rubino; Lucia Siracusa; Francesco Lalicata; Marcello Trizzino; Lucina Titone; Manlio Tolomeo
Journal:  BMC Res Notes       Date:  2012-10-05
  10 in total
  22 in total

Review 1.  Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Authors:  Brady L Stein; Jason Gotlib; Murat Arcasoy; Marie Huong Nguyen; Neil Shah; Alison Moliterno; Catriona Jamieson; Daniel A Pollyea; Bart Scott; Martha Wadleigh; Ross Levine; Rami Komrokji; Rebecca Klisovic; Krishna Gundabolu; Patricia Kropf; Meir Wetzler; Stephen T Oh; Raul Ribeiro; Rita Paschal; Sanjay Mohan; Nikolai Podoltsev; Josef Prchal; Moshe Talpaz; David Snyder; Srdan Verstovsek; Ruben A Mesa
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

Review 3.  Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives.

Authors:  Giuseppe G Loscocco; Alessandro M Vannucchi
Journal:  Int J Hematol       Date:  2022-03-29       Impact factor: 2.490

Review 4.  Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review.

Authors:  Asuka Ogai; Kazuma Yagi; Fumimaro Ito; Hideharu Domoto; Tetsuya Shiomi; Kenko Chin
Journal:  Intern Med       Date:  2021-09-25       Impact factor: 1.282

Review 5.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

6.  Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Authors:  Thamer Sliwa; Christine Beham-Schmid; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Maria Krauth; Peter Krippl; Alois Lang; Andreas Petzer; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2016-12-13       Impact factor: 1.704

Review 7.  The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.

Authors:  Marie Strickland; Lynn Quek; Bethan Psaila
Journal:  Br J Haematol       Date:  2021-10-07       Impact factor: 8.615

Review 8.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 9.  Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Authors:  Jeffrey C Bryan; Srdan Verstovsek
Journal:  Cancer Chemother Pharmacol       Date:  2016-03-26       Impact factor: 3.333

Review 10.  '"Why me, why now?" Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection.

Authors:  M Alexandra Lake; Lyn R Ambrose; Marc C I Lipman; David M Lowe
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.